GBA's "2021 Stock Phantasma"

Please Lord: Let Clinton H.S Boys win!!!

Down 3 at the half this is super stressful/ I have a stress / acid pyloric valve based sickness/
I'm drinking lemonade my pulse is raging. If I was there I would be screaming.
 
OOooopha.
0-1. o_O

Good news/bad news. My boy played good (15 points). They lost. Now we work to rebuild spirit. Basketball is alot like stocks. In both cases you NEED REBOUNDING. (T-shirt tm stoney)

I heard an amazing fact. The amount of Co2 released and carbon damage to the earth by all the shipping on cargo boats is equal to France and England's total output. Wow.

The tops of oil tankers are flat as heck. Why not solar panel the entire tops of these huge tankers and turn all boats into half electric solar powered boats...

And on the cargo side a huge rolling solar canvas that covers all the boxes. You could still sack them to the heavens but the last stack is covered somehow with solar panels.

I mean I never thought we could control global warming it seems a ski slope we cannot get off, but if we want to keep importing cars and crates and make a real Earth saving move here-- Why have none of these companies invented the Giant Solar Boat?

Elon--> Common... Tesla Oil tankers.... and there you can use some of your auto pilot.
 
JMP upgrades Iovance to Outperform with 149% potential upside 05:55 IOVA JMP Securities analyst Reni Benjamin upgraded Iovance Biotherapeutics to Outperform from Market Perform with a $32 price target. The analyst downgraded the shares in May based on the delayed filing of the lifileucel, lack of clarity regarding potency assays, and the abrupt departure of the CEO.

Since then, Iovance presented data showcasing updated results of lifileucel in advanced melanoma as well as initial data on a combination therapy of lifileucel with pembrolizumab. In addition, the interim CEO "has convinced us that one of the new assays to be submitted to the agency should clear the path for a successful" application filing in the first half of 2022, Benjamin tells investors in a research note. The analyst believes Iovance shares "represent a unique investment opportunity" with 36% potential downside and 149% potential upside.

Iovance Is The Gummy Of The Day! I'll be trying to get in.
 
It's a 2 gummy morning folks---

Asana CEO buys 500Kshares of common stock 20:32 ASAN In a regulatory filing, Asana disclosed that its CEO Dustin Moskovitz bought 500K shares of common stock on June 7th in a total transaction size of $19.7M, boosting his stake by about 10%.

ASAN is the 2nd gummy of the day
 
This Berkley Lights has been haunting me. I was taken by the interview I posted here (you can find it)-- basically it was an industry lab guy who was being interviewed by some stock guy and the overall message was all I can tell you is people in the lab biz are using it..

Quick scalps are not for this name. It has to get into the larger account.
 
MGM Resorts price target raised to $52 from $47 at JPMorgan

Myomo initiated with a Buy at Alliance Global Partners

Asana price target raised to $50 from $40 at Baird 06:59 ASAN Baird analyst Rob Oliver raised the firm's price target on Asana to $50 from $40 and keeps an Outperform rating on the shares. The analyst reiterated his bullish stance after the company unveiled a suite of personal-productivity features that aim to bridge the gap between team-agility and individualization.
 
You must log in or register to reply here.
Back
Top